Gilead Sciences
This role serves as the enterprise service owner for Identity and Access Management (IAM), ensuring control effectiveness, governance, and compliance across all Gilead systems. The incumbent leads DOJ Data Security Program initiatives, manages access certification programs, and oversees IAM operational delivery through integrated platforms and managed service providers. Key responsibilities include defining RBAC strategies, enforcing identity lifecycle management processes, and partnering with security and business stakeholders to drive regulatory readiness.
Headquarters
Foster City, California, United States
Company Size
10001+ employees
Founded
1987
Gilead Sciences is a biopharmaceutical company dedicated to transforming patient care by advancing therapeutics in areas like HIV, liver disease, cancer, and inflammation. With a strong commitment to innovation, Gilead leads in the research and development of new medicines, aiming to make the world a healthier place. Their portfolio includes breakthrough therapies and ongoing advancements across multiple therapeutic areas, supported by a robust pipeline of clinical trials. Gilead is recognized for its contributions to public health and its efforts to improve access to vital medications.
Franklin Resources Inc. Decreases Stake in Gilead Sciences, Inc. $GILD
4 hours ago
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum And Mixed Fair Value Signals
1 hour ago
Jefferies initiates Gilead Sciences stock with buy rating
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Gilead Sciences.
27% above the average for this role
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
2 days ago